Clinical significance of androgen receptor expression in triple negative breast cancer‑an immunohistochemistry study

Liu,Ya‑Xuan; Zhang,Ke‑Jing; Tang,Li‑Li

doi:10.3892/ol.2018.8548

Clinical significance of androgen receptor expression in triple negative breast cancer‑an immunohistochemistry study

Authors:
- Ya‑Xuan Liu
- Ke‑Jing Zhang
- Li‑Li Tang
View Affiliations

Affiliations: Department of Breast Surgery, Breast Cancer Prevention and Clinical Research Center, Xiangya Hospital Central South University, Changsha, Hunan 410008, P.R. China
Published online on: April 20, 2018 https://doi.org/10.3892/ol.2018.8548
Pages: 10008-10016

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Androgen receptor (AR) is closely associated with the occurrence and progression of breast cancer; however, the clinical significance of it in triple negative breast cancer (TNBC) has been controversial. There is a limited amount of research regarding the effect of neoadjuvant chemotherapy on AR expression. By examining the expression of AR in patients with TNBC, the aim of the present study is to explore the clinical significance of AR and provide evidence for AR‑directed treatment in TNBC. A total of 188 patients with primary TNBC with complete medical records were included in this retrospective study. Tumor sections from 41 patients (21.8%) were positive for AR, which was more often detected in small tumors (P=0.042) and cases with no lymph node involvement (P=0.032). Among them, 102 were treated with neoadjuvant chemotherapy (NAC). A total of 17 patients (16.7%) exhibited pathological complete response. However, the patient response was irrelevant to AR expression. Matched pathological tissues before and after NAC were collected for 49 cases, suggesting an enrichment of AR‑expressing tumors following chemotherapy (P=0.008). Further analysis indicated that AR expression had no correlation with the disease‑free and overall survival of patients with general TNBC; rather, it predicted a poor survival of the patients with stage III TNBC in comparison with those at earlier stages (P=0.035). AR expression occurs more often in small TNBC tumors or in cases with no lymph node metastasis. It is associated with a poor prognosis of the patients with advanced stages of tumors.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H and Andre F: Precision medicine for metastatic breast cancer-limitations and solutions. Nat Rev Clin Oncol. 12:693–704. 2015. View Article : Google Scholar : PubMed/NCBI
4	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
5	Lumachi F, Santeufemia DA and Basso SM: Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 6:231–239. 2015. View Article : Google Scholar : PubMed/NCBI
6	Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI
7	Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011. View Article : Google Scholar : PubMed/NCBI
8	Steward L, Conant L, Gao F and Margenthaler J: Predictive factors and patterns of recurrence in patients with triple negative breast cancer. Ann Surg Oncol. 21:2165–2171. 2014. View Article : Google Scholar : PubMed/NCBI
9	Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP and Earle CC: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 98:1108–1117. 2006. View Article : Google Scholar : PubMed/NCBI
10	Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
11	Shang Y, Myers M and Brown M: Formation of the androgen receptor transcription complex. Mol Cell. 9:601–610. 2002. View Article : Google Scholar : PubMed/NCBI
12	McNamara KM, Moore NL, Hickey TE, Sasano H and Tilley WD: Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer. 21:T161–T181. 2014. View Article : Google Scholar : PubMed/NCBI
13	Yeh S, Hu Y, Wang P, Xie C, Xu Q, Tsai M, Dong Z, Wang R, Lee T and Chang C: Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med. 198:1899–1908. 2003. View Article : Google Scholar : PubMed/NCBI
14	Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM and Bhargava R: Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 23:205–212. 2010. View Article : Google Scholar : PubMed/NCBI
15	Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW and Lee KS: Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol. 22:1755–1762. 2011. View Article : Google Scholar : PubMed/NCBI
16	Goldenberg IS: Testosterone propionate therapy in breast cancer. JAMA. 188:1069–1072. 1964. View Article : Google Scholar : PubMed/NCBI
17	Garay JP and Park BH: Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res. 2:434–445. 2012.PubMed/NCBI
18	Chia K, O'Brien M, Brown M and Lim E: Targeting the androgen receptor in breast cancer. Curr Oncol Rep. 17:42015. View Article : Google Scholar : PubMed/NCBI
19	Fujii R, Hanamura T, Suzuki T, Gohno T, Shibahara Y, Niwa T, Yamaguchi Y, Ohnuki K, Kakugawa Y, Hirakawa H, et al: Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid Biochem Mol Biol. 144:513–522. 2014. View Article : Google Scholar : PubMed/NCBI
20	Maugeri-Saccà M, Barba M, Vici P, Pizzuti L, Sergi D, De Maria R and Di Lauro L: Aromatase inhibitors for metastatic male breast cancer: Molecular, endocrine, and clinical considerations. Breast Cancer Res Treat. 147:227–235. 2014. View Article : Google Scholar : PubMed/NCBI
21	Qi JP, Yang YL, Zhu H, Wang J, Jia Y, Liu N, Song YJ, Zan LK, Zhang X, Zhou M, et al: Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. Breast Cancer (Auckl). 6:1–8. 2012.PubMed/NCBI
22	McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T and Sasano H: Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol. 133:66–76. 2013. View Article : Google Scholar : PubMed/NCBI
23	Xu H, Eirew P, Mullaly SC and Aparicio S: The omics of triple-negative breast cancers. Clin Chem. 60:122–133. 2014. View Article : Google Scholar : PubMed/NCBI
24	Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, et al: PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 16:4062014. View Article : Google Scholar : PubMed/NCBI
25	Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 138:241–256. 2014. View Article : Google Scholar : PubMed/NCBI
26	Shi SR, Guo J, Cote RJ, Young L, Hawes D, Shi Y, Thu S and Taylor CR: Sensitivity and detection efficiency of a novel two-step detection system (PowerVision) for immunohistochemistry. Appl Immunohistochem. 7:201–208. 1999. View Article : Google Scholar
27	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
28	Chia KM, Liu J, Francis GD and Naderi A: A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia. 13:154–166. 2011. View Article : Google Scholar : PubMed/NCBI
29	Micello D, Marando A, Sahnane N, Riva C, Capella C and Sessa F: Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Arch. 457:467–476. 2010. View Article : Google Scholar : PubMed/NCBI
30	Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG and Carroll JS: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 30:3019–3027. 2011. View Article : Google Scholar : PubMed/NCBI
31	Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
32	McNamara KM, Yoda T, Miki Y, Chanplakorn N, Wongwaisayawan S, Incharoen P, Kongdan Y, Wang L, Takagi K, Mayu T, et al: Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation. Cancer Sci. 104:639–646. 2013. View Article : Google Scholar : PubMed/NCBI
33	Thike AA, Chong Yong-Zheng L, Cheok PY, Li HH, Yip Wai-Cheong G, Bay Huat B, Tse GM, Iqbal J and Tan PH: Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol. 27:352–360. 2014. View Article : Google Scholar : PubMed/NCBI
34	Choi JE, Kang SH, Lee SJ and Bae YK: Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol. 22:82–89. 2015. View Article : Google Scholar : PubMed/NCBI
35	Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 134:e48–e72. 2010.PubMed/NCBI
36	Zhang L, Fang C, Xu X, Li A, Cai Q and Long X: Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: A meta-analysis. Biomed Res Int. 2015:3574852015.PubMed/NCBI
37	Mrklić I, Pogorelić Z, Ćapkun V and Tomić S: Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem. 115:344–348. 2013. View Article : Google Scholar : PubMed/NCBI
38	Ricciardi GR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, Franchina T, Tuccari G and Adamo V: Androgen receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients. PloS One. 10:e01283682015. View Article : Google Scholar : PubMed/NCBI
39	Honma N, Horii R, Iwase T, Saji S, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F and Sakamoto G: Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol. 26:3727–3734. 2008. View Article : Google Scholar : PubMed/NCBI
40	Anestis A, Karamouzis MV, Dalagiorgou G and Papavassiliou AG: Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? Cancer Treat Rev. 41:547–553. 2015. View Article : Google Scholar : PubMed/NCBI
41	Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, et al: Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 130:477–487. 2011. View Article : Google Scholar : PubMed/NCBI
42	Lehmann BD and Pietenpol JA: Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 232:142–150. 2014. View Article : Google Scholar : PubMed/NCBI
43	Luo X, Shi YX, Li ZM and Jiang WQ: Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 29:585–590. 2010. View Article : Google Scholar : PubMed/NCBI
44	Gasparini P, Fassan M, Cascione L, Guler G, Balci S, Irkkan C, Paisie C, Lovat F, Morrison C, Zhang J, et al: Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One. 9:e885252014. View Article : Google Scholar : PubMed/NCBI
45	Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A and Amir E: Androgen receptor expression and outcomes in early breast cancer: A systematic review and meta-analysis. J Natl Cancer Inst. 106:djt3192014. View Article : Google Scholar : PubMed/NCBI
46	Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA and Tamimi RM: Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 17:1867–1874. 2011. View Article : Google Scholar : PubMed/NCBI
47	Sutton LM, Cao D, Sarode V, Molberg KH, Torgbe K, Haley B and Peng Y: Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol. 138:511–516. 2012. View Article : Google Scholar : PubMed/NCBI
48	McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, Castle EP, Gray RJ, Wasif N, Goetz MP, et al: Androgen receptor-positive triple negative breast cancer: A unique breast cancer subtype. Ann Surg Oncol. 21:361–367. 2014. View Article : Google Scholar : PubMed/NCBI
49	Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C and Gerald WL: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 25:3994–4008. 2006. View Article : Google Scholar : PubMed/NCBI
50	Tsutsumi Y: Apocrine carcinoma as triple-negative breast cancer: Novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn J Clin Oncol. 42:375–386. 2012. View Article : Google Scholar : PubMed/NCBI
51	Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H and Kantoff PW: Current treatment strategies for advanced prostate cancer. Int J Urol. 2017.
52	Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 25:1596–1605. 2007. View Article : Google Scholar : PubMed/NCBI
53	Cuenca-López MD, Montero JC, Morales JC, Prat A, Pandiella A and Ocana A: Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer. 14:3022014. View Article : Google Scholar : PubMed/NCBI
54	Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, et al: Phase II Trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 19:5505–5512. 2013. View Article : Google Scholar : PubMed/NCBI
55	Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, et al: Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. JCO20167134952018.
56	Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, et al: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 27:3742–3748. 2009. View Article : Google Scholar : PubMed/NCBI
57	O'Shaughnessy J, Campone M, Brain E, Neven P, Hayes D, Bondarenko I, Griffin TW, Martin J, De Porre P, Kheoh T, et al: Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. Ann Oncol. 27:106–113. 2015. View Article : Google Scholar : PubMed/NCBI
58	Narayanan R, Coss CC and Dalton JT: Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol: pii. S0303-7207(17)30340-4. 2017.
59	Narayanan R, Ahn S, Cheney MD, Yepuru M, Miller DD, Steiner MS and Dalton JT: Selective Androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial: Mesenchymal stem cell signaling. PLoS One. 9:e1032022014. View Article : Google Scholar : PubMed/NCBI